Abstract: Radically polymerizable dental material, which contains a combination of a thiourea derivative and a hydroperoxide according to the following Formula (I) as initiator system for the radical polymerization:

Abstract: The present invention provides a solid mask and a preparation method thereof. The solid mask includes a hydrophobic substrate layer and a nanofiber layer, the nanofiber layer has a three-dimensional structure and is electro-spun onto the hydrophobic substrate layer through uniaxial electrostatic spinning technology, and the nanofiber layer is prepared by the following food-grade raw materials in parts by mass: 10 to 30 parts of gelatin, 1 to 30 parts of soya bean lecithin and 0.1 to 10 parts of a functional substance. The present invention provides a solid mask, using gelatin and soya bean lecithin as the framework. The nanofiber layer is a three-dimensional laminate made of fibers having a diameter of a few hundred nanometers. The nanofiber layer has a membrane structure similar to the extracellular matrix. The raw materials of the solid mask are all food-grade raw materials or natural extracts.

Abstract: A cleansing composition for cleansing the skin, comprising by weight of the composition, — 20 to 65 wt. % of one or more polyols; and —5 to 25 wt. % of thickeners, comprising a combination of: a) inorganic thickener selected from silica, chalk, talc, clay and combinations thereof; b) cellulosic thickener selected from cellulose, cellulose ether, cellulose ester and combinations thereof; wherein the weight ratio of the inorganic thickener to the cellulosic thickener is in the range of 4:1 to 40:1; —4 to 12 wt. % of non-soap anionic surfactant; —0 to 8 wt. % of amphoteric surfactant; and wherein the weight ratio of the one or more polyols to the thickeners is in the range of 1:1 to 13:1 and wherein the viscosity of the composition is in the range of 200 to 400 Pa-s, measured at 25° C. after 1 minute at 5 rpm.

Abstract: The present invention is directed to a method for improving the occlusiveness of a topical pharmaceutical or cosmetic formulation in use in a patient in need thereof, comprising adding to the formulation at least 0.1- to about 10% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof. The present invention is also directed to a method for maintaining skin barrier efficiency of the stratum corneum of a patient in need thereof, comprising applying to the skin of said patient a pharmaceutical or cosmetic formulation containing at least 3% w/w of one or more of a monofatty acid ester of glycerin and/or one or more of a monofatty acid ester of glycol, or mixtures thereof.

Abstract: An antimicrobial composition with a synergistic combination of ingredients is described. Cosmetic compositions containing the antimicrobial composition with improved preservation properties are also described. The cosmetic compositions are effective in treating the skin to cleanse, moisturize and to reduce the effects of aging and photo damage and treat other skin conditions after being topically applied.

Abstract: The present application relates to compounds, formulations, kits and methods of use in the cosmetics field. A cosmetic formulation comprising a diester compound of Formula (I) or Formula (II), or a combination thereof, and one or more cosmetically acceptable carriers or excipients.

Abstract: Hair dye composition and method of dyeing hair that targets only at least one grey part using a permanent hair dye component comprising a specific volume percentage of a particulate pigment to permanent hair dye component. The purpose of some embodiments of the invention is to delay the need for women to dye their hair in full. At least one pigment particle (about 0.0770 ml or about 1/64th of a teaspoon) may be added to a bottle of 71 ml of permanent hair dye, which allows the permanent hair dye composition to become visible and allows for more accuracy during application. Using small quantities of 5 cc per application (hair dye: 2.5 ml; developer: 2.5 ml) reduces the amount of dye applied to needless areas of the hair. The use of a make-up sponge stick allows for better accuracy. The composition is multi-use, and provides for 28 applications (71 ml bottle of dye and 71 ml of developer), and will save users time and money.

Abstract: Sunscreen compositions containing bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT) and zinc oxide, especially non-nano zinc oxide materials, with synergistic effects on enhancing in vivo sun protection factor (SPF) and UVA protection factor (PFA) values, and methods of preparation and applications thereof are disclosed.

Abstract: A device and protective composition is described that is used in the context of first aid for skin contact with acids, bases, oxidizing agents, formaldehyde and fluorides serving to neutralize and inactivate the chemicals. The device comprises a two-chamber applicator that contains a first preparation in a first chamber, such as an antioxidant, and a second preparation in a second chamber, such as a solution that contains a buffer and a calcium salt. The two preparations are mixed just before application and are applied to the affected areas by the device.

Abstract: Provided is a polymer-based antimicrobial composition that is non-toxic, water soluble, and that mitigates the transmission of infectious diseases from surfaces. The composition comprises a cationic polymer, at least one adhesion promoter, optionally organic and/or inorganic particles that are photocatalytically active in visible light, and a carrier, in which the components of the composition are not covalently bound to one another. Also provided is an antimicrobial composition that comprises at least (i) a polyethylenimine-based polymer and a carrier or (ii) an organic and/or inorganic particle that is photocatalytically active in visible light, an adhesion promoter, and a carrier. The antimicrobial compositions can be applied to disinfect a surface and to form residual self-sanitizing films on the surface that are removable.

Abstract: Disclosed are a method for preparing a hydroalcoholic extract obtained from a biomass of the shoots of a plant from the family of Plumbaginaceae, a butanol extract of Armenia maritima, a method for the preparation thereof, the use thereof, and compositions containing same.

Abstract: A skin care composition includes a carrier substance and a proportion of lactic acid bacteria and/or their metabolic products, wherein the metabolic products are included in the skin care composition in a form of a ferment obtained during a cultivation of the lactic acid bacteria. The skin care composition additionally contains chitosan or a suitable chitosan derivative.

Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.

Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.

Abstract: Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

Abstract: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.

Abstract: A method for administering solid water particles to prevent bacteria growth in living organisms utilizes a solid water particle (SWP) solution to attract and kill a bacterium through polarization. The method inhibits growth of a bacterium or an enveloped virus with an inorganic solution comprised substantially of SWP. The SWP kill the bacterium by providing a solution comprised substantially of SWP having inherent dipole characteristics that generate an electric field. The generated electric field attracts a bacterium to the SWP. Once engaged, the bacterium cannot move. The electric field also creates sufficient internal pressure in the bacterium, which bursts the cell walls of the bacterium, thereby killing bacterium. This mechanism also kills superbug, which are drug resistant bacteria. The method is also efficacious for killing enveloped viruses in the same manner. Further, administering the SWP solution into the mouth for a duration, helps reduce tooth pain and treat periodontal diseases.

Abstract: Apparatuses for use with a pharmaceutically acceptable carrier. The apparatus can include a partial power source, which in turn includes electrodes or materials that are configured to generate an electrical potential upon contacting or being exposed to an ionic solution. The apparatus can further include a circuit electrically or communicatively coupled to the partial power source. The circuit can generate various types of signals, such as RF signals, when powered by the partial power source. The circuit is stably fittable to the pharmaceutically acceptable carrier. The apparatus can further include a barrier, a protective layer, or a membrane that isolates the electrodes or materials from the ionic solution and is configured to be dissolved by the ionic solution.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Abstract: A two-compartment capsule includes a body, a diaphragm between which seals off the body and provides a first compartment to hold a first ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second ingredient. This disclosure also provides certain ranges for the volumes of the first compartment and the second compartment, as well as a volume ratio of the first compartment to the second compartment, lengths of the first and second compartments, and the length of contact between a sidewall of the diaphragm and a sidewall of the body. Furthermore, particular ingredients and formulations for the two-compartment capsule where volume is critical for a therapeutic effect are disclosed.

Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

Abstract: Granulations with granules having a high loading of an active pharmaceutical ingredient are disclosed. The active pharmaceutical ingredient has a high aqueous water solubility. The granules have a narrow particle size distribution and a smooth exterior surface.

Abstract: The present invention relates to the localized delivery of nucleic acids to cells using polyelectrolyte assemblies in the form of particles that are prepared by layer-by-layer deposition of nucleic acid and specific polycation. It also relates to compositions comprising said particles and methods for the treatment of disorders or diseases by administration of such particles.

Abstract: The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.

Abstract: The invention relates to self-assembled nanofibers of chitosan and bioactive compounds for use as nutraceuticals or drugs. Suitable bioactive compounds include molecules of a low molecular size with acid or lactone groups, aromatic rings and hydroxyls. The nanofibers are absorbed, without degradation, in the small intestine, containing and protecting the bioactive compounds until they reach target organs. The nanofibers also cross the blood-brain barrier, allowing the compounds to reach the brain where they act as a controlled release system. If the bioactive compounds are neuroprotectors, the nanofibers can treat or prevent neurodegenerative diseases, strokes and other diseases related to aging or associated with oxidative stress. The invention also relates to a method for obtaining the nanofibers involving mixing chitosan with the bioactive compounds and allowing self-assembly. The invention further relates to a dosage form containing the nanofibers, particularly for oral administration.

Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment, as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of a natural pimarane diterpenoid extract of Hymenocrater elegans, or a derivative, analogue, or homolog thereof. Compounds based upon this natural extract have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

Abstract: Pharmaceutical formulations comprising ketamine, propofol, and a lipid are provided. Methods of making the formulations and methods of using the formulations to provide sedation, amnesia, analgesia, anxiolysis, and/or stable hemodynamics are also provided.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: This document relates to methods and materials involved in treating a mammal having, or at risk of developing, cytokine release syndrome (CRS). For example, a mammal having, or at risk of developing, CRS can be treated by administering one or more biguanides (e.g., metformin) to the mammal.

Abstract: The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.

Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.

Abstract: A method is provided for treating a Mendelian disorder of the epigenetic machinery in a subject in need thereof. In particular, the method comprises administering a therapeutically effective amount of an agent that restores balance between open and closed chromatin states at one or more target genes, wherein the agent that restores balance between open and closed chromatin states at one or more target genes is an agent that ameliorates the effect of a defective gene encoding a component of the epigenetic machinery.

Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

Abstract: Described herein are prodrugs of cysteamine and pharmaceutically acceptable salts, solvates, and esters thereof. Also described herein are pharmaceutical compositions comprising prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof, and methods of treatment comprising administering prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof.

Abstract: The present invention provides a composition for preventing or mitigating dementia in a subject comprising a mixture of tocotrienols, tocopherol, squalene and B vitamin, and a pharmaceutically acceptable carrier.

Abstract: Chemical compounds are provided that are useful in the treatment of diseases associated with an activity of a 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzyme in pathological eukaryotic cells. In particular, compounds that exhibit inhibitory activity upon 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzymes and their use in the treatment of cancer and/or parasitic diseases are provided.

Abstract: Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

Abstract: The present invention relates to novel halogen-substituted compounds, to processes for their preparation and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids.

Abstract: Effective implantable medical devices and methods for reducing and treating acute pain by providing local anesthesia and nerve blockade using an imidazoline compound, such as clonidine are provided. In some embodiments, there is an injectable pharmaceutical composition comprising a therapeutically effective amount of imidazoline compound in a liquid pharmaceutical carrier, where the imidazoline compound provides local anesthesia and nerve block to the target tissue site which is a dorsal root ganglion, peripheral nerve fiber and/or peripheral nerve root.

Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

Abstract: Provided are epithelial cell spheroids including spheroids that have apical membranes and cilia that face towards the interior core of the spheroid and spheroids that have apical membranes and cilia that face away from the interior core of the spheroid. Also provided methods of making and using such spheroids.

Abstract: The present disclosure relates to an ADAM9 inhibitor compound of formula (I), including salts, hydrates and stereoisomers thereof, compositions thereof, and methods of use therefor, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).